IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : FENG et al. Art Unit: 1617 Serial No. : 10/718,948 : November 20, 2003 Examiner: Carlic K. HUYNH Filed : METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE For b-ADRENERGIC PATHWAYS I hereby certify that this correspondence is being transmitted via The Office electronic filing system in accordance with 37 CFR 1.6(a)(4) July 13,2007
(Date of Transmission) Anna M. Pignaloni
(Name of applicant, assignee, Registered Representative or Depositor) July 13,2007
(Date of Signature) Commissioner for Patents Washington, D.C. 20231 STATEMENT UNDER 37 C.F.R. §1.97(e) In accordance with 37 C.F.R. §1.97(e), certification is hereby made that: Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office, in a counterpart foreign application, and, to the

knowledge of the undersigned after making reasonable inquiry, no item

of information contained in this Information Disclosure Statement,

was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

Samuel M. Kais Reg. No. 42,705

Attorney for Applicants

Scios Inc.

c/o Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933

Phone: (650) 564-4146 Fax: (650) 564-2101